$ARCT
Arcturus Therapeutics Holdings Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020038980 Filed on August 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q2
Revenue $2.333M $2.322M $10.15M
YoY Change -29.69% -77.13% 325.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.570M $4.420M $3.460M
YoY Change 43.56% 27.75% -57.96%
% of Gross Profit
Research & Development $17.70M $7.944M $7.269M
YoY Change 150.94% 9.29% 72.05%
% of Gross Profit
Depreciation & Amortization $220.0K $210.0K $180.0K
YoY Change 22.22% 16.67% -30.77%
% of Gross Profit
Operating Expenses $17.70M $7.944M $10.73M
YoY Change 150.94% -25.93% 153.85%
Operating Profit -$20.94M -$10.04M -$572.0K
YoY Change 174.92% 1655.59% -94.32%
Interest Expense -$70.00K -$220.0K -$110.0K
YoY Change -138.89% 100.0% -191.67%
% of Operating Profit
Other Income/Expense, Net -$113.0K
YoY Change
Pretax Income -$21.00M -$10.26M -$690.0K
YoY Change 182.64% 1386.96% -93.07%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$21.00M -$10.26M -$685.0K
YoY Change 182.58% 1398.25% -93.12%
Net Earnings / Revenue -900.3% -441.99% -6.75%
Basic Earnings Per Share
Diluted Earnings Per Share -$915.4K -$546.0K -$66.28K
COMMON SHARES
Basic Shares Outstanding 24.39M 19.89M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $307.0M $136.1M $55.80M
YoY Change 313.75% 143.91% 40.2%
Cash & Equivalents $307.0M $136.1M $55.84M
Short-Term Investments
Other Short-Term Assets $4.600M $3.100M $22.00K
YoY Change 13839.39% 13990.91% -95.6%
Inventory
Prepaid Expenses $1.659M
Receivables $2.400M $2.800M $5.817M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $314.1M $142.0M $63.34M
YoY Change 295.59% 124.19% 51.89%
LONG-TERM ASSETS
Property, Plant & Equipment $8.300M $7.800M $1.986M
YoY Change 12.16% 292.75% 4.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0%
Other Assets $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $8.400M $7.900M $7.602M
YoY Change 7.49% 3.92% 192.38%
TOTAL ASSETS
Total Short-Term Assets $314.1M $142.0M $63.34M
Total Long-Term Assets $8.400M $7.900M $7.602M
Total Assets $322.5M $149.9M $70.94M
YoY Change 269.78% 111.31% 60.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.500M $4.400M $3.187M
YoY Change 61.97% 38.06% 13.82%
Accrued Expenses $12.00M $7.600M $3.497M
YoY Change 79.75% 117.33% -14.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.00M $23.00M $16.41M
YoY Change 29.1% 40.12% -10.31%
LONG-TERM LIABILITIES
Long-Term Debt $15.10M $15.10M $9.980M
YoY Change 50.76% 51.3%
Other Long-Term Liabilities $17.80M $18.40M $22.90M
YoY Change -9.18% -19.65% 175.9%
Total Long-Term Liabilities $32.90M $33.50M $9.980M
YoY Change 228.47% 235.67% 20.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.00M $23.00M $16.41M
Total Long-Term Liabilities $32.90M $33.50M $9.980M
Total Liabilities $60.90M $56.50M $49.32M
YoY Change 18.67% 14.55% 86.12%
SHAREHOLDERS EQUITY
Retained Earnings -$53.25M
YoY Change
Common Stock $13.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $261.6M $93.42M $21.62M
YoY Change
Total Liabilities & Shareholders Equity $322.5M $149.9M $70.94M
YoY Change 269.78% 111.31% 60.14%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$21.00M -$10.26M -$685.0K
YoY Change 182.58% 1398.25% -93.12%
Depreciation, Depletion And Amortization $220.0K $210.0K $180.0K
YoY Change 22.22% 16.67% -30.77%
Cash From Operating Activities -$15.88M -$8.490M $9.340M
YoY Change 459.15% -190.9% -213.9%
INVESTING ACTIVITIES
Capital Expenditures -$440.0K -$470.0K -$260.0K
YoY Change 175.0% 80.77% -74.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$440.0K -$470.0K -$260.0K
YoY Change 175.0% 80.77% -102.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 187.2M 85.60M 15.55M
YoY Change 778.14% 450.48% 4342.86%
NET CHANGE
Cash From Operating Activities -15.88M -8.490M 9.340M
Cash From Investing Activities -440.0K -470.0K -260.0K
Cash From Financing Activities 187.2M 85.60M 15.55M
Net Change In Cash 170.9M 76.64M 24.63M
YoY Change 832.86% 211.17% 487.83%
FREE CASH FLOW
Cash From Operating Activities -$15.88M -$8.490M $9.340M
Capital Expenditures -$440.0K -$470.0K -$260.0K
Free Cash Flow -$15.44M -$8.020M $9.600M
YoY Change 476.12% -183.54% -233.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
698000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1101000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
6354000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
403000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75305000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
816000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1950000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
13642000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
802000
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201409Member
us-gaap Depreciation And Amortization
DepreciationAndAmortization
394000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
349000
us-gaap Share Based Compensation
ShareBasedCompensation
1950000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2302000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1442000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
773000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3619000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1536000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
12773000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4420000
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity File Number
EntityFileNumber
001-38942
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0595345
dei Entity Address Address Line1
EntityAddressAddressLine1
10628 Science Center Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
900-2660
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24388176
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20610000
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20610000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2322000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10042000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18794000
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10412000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7569000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75305000
CY2019Q4 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
2750000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4530000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2181000
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1608000
CY2019Q4 arct Accrued Cystic Fibrosis Foundation Liability
AccruedCysticFibrosisFoundationLiability
1949000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
827000
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
500000
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
400000
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
93407
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
80585
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1101000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
403000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
300000
us-gaap Operating Lease Cost
OperatingLeaseCost
600000
us-gaap Share Based Compensation
ShareBasedCompensation
802000
arct Loss From Equity Method Investments
LossFromEquityMethodInvestments
263000
arct Loss From Equity Method Investments
LossFromEquityMethodInvestments
288000
arct Other Non Cash Interest Expense
OtherNonCashInterestExpense
654000
arct Other Non Cash Interest Expense
OtherNonCashInterestExpense
428000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
650000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1336000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1043000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2798000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20352000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3929000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
611000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
344000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-611000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-344000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75305000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
816000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
85721000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15546000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
64758000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19131000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71460000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36816000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136218000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55947000
us-gaap Interest Paid Net
InterestPaidNet
180000
us-gaap Interest Paid Net
InterestPaidNet
340000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
674000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5868000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
44000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
16000
CY2020Q2 arct Lessee Operating Leases Liability Payments Due After Year Four
LesseeOperatingLeasesLiabilityPaymentsDueAfterYearFour
314000
us-gaap Dividends
Dividends
0
us-gaap Dividends
Dividends
0
CY2019Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2179000
arct Contract With Customer Asset Additions For Revenue Recognized
ContractWithCustomerAssetAdditionsForRevenueRecognized
2171000
CY2020Q2 arct Grants Received From Government
GrantsReceivedFromGovernment
5000000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55840000
CY2019Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
107000
arct Contract With Customer Asset Deductions For Cash Collections
ContractWithCustomerAssetDeductionsForCashCollections
1521000
CY2020Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2829000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
23579000
arct Contract With Customer Liability Additions For Advanced Billings
ContractWithCustomerLiabilityAdditionsForAdvancedBillings
2171000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5185000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2575000
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2234000
CY2020Q2 arct Accrued Cystic Fibrosis Foundation Liability
AccruedCysticFibrosisFoundationLiability
3010000
CY2020Q2 arct Accrued Singapore Economic Development Board Liability
AccruedSingaporeEconomicDevelopmentBoardLiability
672000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1337000
CY2020Q2 arct Clinical Accruals Current
ClinicalAccrualsCurrent
299000
CY2020Q2 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
4331000
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1300000
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7500000
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
6700000
CY2020Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
200000
CY2019Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
200000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1950000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
802000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P13M
CY2020Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P1M
CY2020Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease may be extended for one twelve-month period;
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
992000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1427000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1349000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1390000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1432000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6904000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1173000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
5731000
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.084
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
500000
us-gaap Operating Lease Cost
OperatingLeaseCost
900000

Files In Submission

Name View Source Status
0001564590-20-038980-index-headers.html Edgar Link pending
0001564590-20-038980-index.html Edgar Link pending
0001564590-20-038980.txt Edgar Link pending
0001564590-20-038980-xbrl.zip Edgar Link pending
arct-10q_20200630.htm Edgar Link pending
arct-20200630.xml Edgar Link completed
arct-20200630.xsd Edgar Link pending
arct-20200630_cal.xml Edgar Link unprocessable
arct-20200630_def.xml Edgar Link unprocessable
arct-20200630_lab.xml Edgar Link unprocessable
arct-20200630_pre.xml Edgar Link unprocessable
arct-ex311_7.htm Edgar Link pending
arct-ex312_10.htm Edgar Link pending
arct-ex321_12.htm Edgar Link pending
arct-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending